Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 6/20 | 0.89 |
| ▸ | ABL1 | P00519 | 10/20 | 0.78 |
| ▸ | SRC | P12931 | 8/20 | 0.78 |
| ▸ | EGFR | P00533 | 3/20 | 0.78 |
| ▸ | FYN | P06241 | 3/20 | 0.78 |
| ▸ | YES1 | P07947 | 3/20 | 0.78 |
| ▸ | LYN | P07948 | 3/20 | 0.78 |
| ▸ | HCK | P08631 | 3/20 | 0.78 |
| ▸ | KIT | P10721 | 3/20 | 0.78 |
| ▸ | BCR | P11274 | 3/20 | 0.78 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.78 |
| ▸ | PKMYT1 | Q99640 | 3/20 | 0.78 |
| ▸ | EPHB6 | O15197 | 2/20 | 0.78 |
| ▸ | CSF1R | P07333 | 2/20 | 0.78 |
| ▸ | RET | P07949 | 2/20 | 0.78 |
| ▸ | BRAF | P15056 | 2/20 | 0.78 |
| ▸ | EPHA1 | P21709 | 2/20 | 0.78 |
| ▸ | EPHA2 | P29317 | 2/20 | 0.78 |
| ▸ | EPHA3 | P29320 | 2/20 | 0.78 |
| ▸ | EPHA8 | P29322 | 2/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL773489 | 0.94 | LCK (1.00) | LCKABL1SRCEGFRFYN | |
| SCHEMBL20042596 | 0.90 | LCK (0.84) | LCKABL1SRCEGFRFYN | |
| SCHEMBL13626293 | 0.90 | ABL1 (0.89) | LCKABL1SRCEGFRFYN | |
| SCHEMBL23514174 | 0.90 | SIK2 (0.76) | LCKABL1SRCEGFRFYN | |
| SCHEMBL20048491 | 0.89 | LCK (0.70) | LCKABL1SRCEGFRFYN | |
| SCHEMBL773969 | 0.89 | LCK (0.82) | LCKABL1SRCEGFRFYN | |
| SCHEMBL20042552 | 0.88 | ABL1 (0.86) | LCKABL1SRCEGFRFYN | |
| Dasatinib Anhydrous SCHEMBL28350326 | 0.88 | ABL1 (1.00) | LCKABL1SRCEGFRFYN | |
| Dasatinib Anhydrous SCHEMBL29381185 | 0.88 | ABL1 (1.00) | LCKABL1SRCEGFRFYN | |
| Dasatinib Anhydrous SCHEMBL8226 | 0.88 | ABL1 (1.00) | LCKABL1SRCEGFRFYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230287510-A1 | COMPOSITIONS, PANELS, AND METHODS FOR CHARACTERIZING CHRONIC LYMPHOCYTIC LEUKEMIA | THE BROAD INSTITUTE, INC. (US) | 2023-09-14 | — | — | US | disclosed |
| US-10800771-B2 | Process for the preparation of dasatinib polymorph | NATCO PHARMA LIMITED (IN) | 2020-10-13 | — | — | US | disclosed |
| US-20190292177-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF DASATINIB POLYMORPH | NATCO PHARMA LIMITED (IN) | 2019-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10800771-B2 | Process for the preparation of dasatinib polymorph | ABL1, NOP56, SRSF6 | LCK 314/4885ABL1 1/4885SRC 74/4885 |
| US-20190292177-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF DASATINIB POLYMORPH | NOP56, ABL1, SRSF6 | LCK 315/4885ABL1 2/4885SRC 106/4885 |
| US-20230287510-A1 | COMPOSITIONS, PANELS, AND METHODS FOR CHARACTERIZING CHRONIC LYMPHOCYTIC LEUKEMIA | BCL9, BCL9L, BCL6B | LCK 974/4885ABL1 84/4885SRC 1588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.